FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
To observe and evaluate the efficacy and safety of FOLFOX/FOLFIRI± target-directed regimen containing Levofolinic Acid (Zuoyu ®) in first-line treatment of unresectable or metastatic colorectal cancer
Unresectable or Metastatic Colorectal Cancer
DRUG: FOLFOX/FOLFIRI
Objective response rate (ORR), The proportion of patients whose best overall response (BOR) is complete response (CR) or partial response (PR) assessed by iRECIST v1.1, 2 years
Progression-free survival (PFS), The date from random to the first occurrence of disease progression or death from any cause, whichever comes first, 2years|Disease control rate (DCR), The proportion of patients whose BOR is CR, PR, and stable disease (SD) assessed, 2years
To observe and evaluate the efficacy and safety of FOLFOX/FOLFIRI± target-directed regimen containing Levofolinic Acid (Zuoyu ®) in first-line treatment of unresectable or metastatic colorectal cancer